On September 30, 2024, MediciNova, Inc. (MNOV) announced that MN-166 (ibudilast) will be evaluated in a National Institutes of Health (NIH) - Neurological Disorders and Stroke (NINDS) sponsored Expanded Access Protocol (EAP) trial that will be supported by a $22 million grant to an academic group. The EAP trial will enroll approximately 200 patients with amyotrophic lateral sclerosis (ALS) and will measure MN-166's effect on neurofilament light, a biomarker for neuron damage. MediciNova will provide investigational drug, regulatory support, and safety monitoring support. The EAP program allows patients with serious or life-threatening diseases or conditions to gain access to an investigational product for treatment outside of a clinical trial when no effective therapy options exist.
